A Double-Blind, Randomized, Dose-Escalating Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Dose SHR-4658 in Healthy Volunteers or Volunteers With Elevated Blood Pressure
Latest Information Update: 21 Nov 2025
At a glance
- Drugs SHR 4658 (Primary)
- Indications Hypertension
- Focus Adverse reactions
- Sponsors Beijing Suncadia Pharmaceuticals
Most Recent Events
- 21 Nov 2025 New trial record